Results 81 to 90 of about 6,459 (257)

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes [PDF]

Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight.
D'Alessio David, Nauck Michael A, Herschtal Alan, Menon Venu, Nissen Steven E, Sattar Naveed, Zinman Bernard, Nishiyama Hiroshi, Basile Jan, McGuire Darren K, Weerakkody Govinda, Nicholls Stephen J, Wiese Russell J, Giorgino Francesco, Bhatt Deepak L, Várkonyi Tamás, Miller Debra, Kollaborációs szervezet: SURPASS-CVOT Investigators, Davies Melanie J, Lincoff A Michael, Kellerer Monika, Broder Jonathan C, Pavo Imre, Ji Linong, Kahn Steven E, Zoungas Sophia, Buse John B, et al., Del Prato Stefano   +28 more
core   +1 more source

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

, 2023
Tirzepatide is a unimolecular co-agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the ...
Mette M. Rosenkilde, Juris J. Meier, Holst, Jens J., Lærke S. Gasbjerg, Jens J. Holst, Meier, Juris J., Filip K. Knop, Knop, Filip K., Rosenkilde, Mette M., Gasbjerg, Lærke S.   +9 more
core   +1 more source

Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus

Journal of Lipid and Atherosclerosis
Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GLP-1) receptor agonist to be approved for the treatment of diabetes mellitus.
Sakiko Terui, Taichi Minami, Keita Nakamura, Yasuo Terauchi   +3 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model

Frontiers in Endocrinology
IntroductionParkinson’s disease (PD) is a progressive neurodegenerative disorder for which there is no cure. Diabetes is one of the risk factors for developing PD.
Zhang Lingyu, Feng Peng, Zhong Wanting, Jin Qianqian, Zijuan Zhang, Bo Bai, Guofang Xue, Christian Hölscher   +7 more
doaj   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Tirzepatide for Obesity Treatment and Diabetes Prevention.

BackgroundObesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in ...
Aronne, Louis J, Wharton, Sean, Wilding, John PH, Battula, Ramakrishna, SURMOUNT-1 Investigators, Jouravskaya, Irina, Halpern, Bruno, Perreault, Leigh, Bunck, Mathijs C, Jastreboff, Ania M, Stefanski, Adam, Ahmad, Nadia N, le Roux, Carel W, Zhang, Shuyu   +13 more
core   +2 more sources

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source